Details of the Drug

General Information of Drug (ID: DMETYK5)

Drug Name

Triazolam

Synonyms

Clorazolam; Halcion; Hypnostat; Novidorm; Novodorm; Songar; Triazolamum; Trilam; Apo Triazo; Apotex Brand of Triazolam; Gen Triazolam; Genpharm Brand of Triazolam; Gerard Brand of Triazolam; Pfizer Brand of Triazolam; Triazolam Pfizer Brand; TGAR01H; U 33030; Alti-Triazolam; Apo-Triazo; Gen-Triazolam; Halcion (TN); Halcion (triazolam); Hypam (TN); Novo-Triolam; Triazolamum [INN-Latin]; Trilam (TN); U 33,030; U-33030; U33,030; Apo-Triazo (TN); U-33,030; Triazolam (JAN/USP/INN); Triazolam [USAN:BAN:INN:JAN]; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-[2-chlorophenyl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Hypnotics and Sedatives

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

343.2

Logarithm of the Partition Coefficient (xlogp)

2.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability: The bioavailability of drug is 44% []
Clearance: The drug present in the plasma can be removed from the body at the rate of 3 mL/min/kg [3]
Elimination: 2% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 - 5.5 hours [3]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0208 micromolar/kg/day [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.1% [3]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.58 L/kg [3]
Water Solubility: The ability of drug to dissolve in water is measured as 0.045 mg/mL [2]

Chemical Identifiers

Formula: C17H12Cl2N4
IUPAC Name: 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Canonical SMILES: CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl
InChI: InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3
InChIKey: JOFWLTCLBGQGBO-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5556
ChEBI ID: CHEBI:9674
CAS Number: 28911-01-5
DrugBank ID: DB00897
TTD ID: D0U3LS
VARIDT ID: DR00865
INTEDE ID: DR1637
ACDINA ID: D00701

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Modulator	[5]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[6]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Triazolam (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Altered absorption of Triazolam due to GI dynamics variation caused by Sodium bicarbonate.	Acidosis [5C73]	[8]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Triazolam caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[9]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Triazolam caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[10]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Triazolam and Oliceridine.	Acute pain [MG31]	[11]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Triazolam due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[10]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Triazolam due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[10]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Triazolam caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[12]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Triazolam caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[13]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Triazolam caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Triazolam caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Triazolam caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[15]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Triazolam caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[16]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Triazolam caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[17]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Triazolam caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Tucatinib	DMBESUA	Major	Decreased metabolism of Triazolam caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[19]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Triazolam caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Triazolam and Dihydrocodeine.	Chronic pain [MG30]	[21]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Triazolam and Remifentanil.	Corneal disease [9A76-9A78]	[11]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Triazolam caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[13]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Triazolam caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[22]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Triazolam and Ethanol.	Cystitis [GC00]	[23]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Triazolam caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[24]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Triazolam and Esketamine.	Depression [6A70-6A7Z]	[13]
SODIUM CITRATE	DMHPD2Y	Minor	Altered absorption of Triazolam due to GI dynamics variation caused by SODIUM CITRATE.	Discovery agent [N.A.]	[8]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Triazolam caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Triazolam caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Triazolam caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[27]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Triazolam caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[19]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Triazolam caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[19]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Triazolam caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[19]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Triazolam caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[28]
Simeprevir	DMLUA9D	Moderate	Decreased metabolism of Triazolam caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[29]
Telaprevir	DMMRV29	Major	Decreased metabolism of Triazolam caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[28]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Triazolam caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[30]
Rifampin	DMA8J1G	Minor	Increased metabolism of Triazolam caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[31]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Triazolam caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[32]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Triazolam caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Triazolam caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Saquinavir	DMG814N	Major	Decreased metabolism of Triazolam caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Triazolam caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Didanosine	DMI2QPE	Minor	Altered absorption of Triazolam due to GI dynamics variation caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[8]
Darunavir	DMN3GCH	Major	Decreased metabolism of Triazolam caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Triazolam caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Probenecid	DMMFWOJ	Minor	Decreased metabolism of Triazolam caused by Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[35]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Triazolam caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[36]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Triazolam caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[37]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Triazolam caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[38]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Triazolam caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[39]
Ceritinib	DMB920Z	Major	Decreased metabolism of Triazolam caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[19]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Triazolam caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[40]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Triazolam caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[10]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Triazolam caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[10]
Idelalisib	DM602WT	Major	Decreased metabolism of Triazolam caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[19]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Triazolam caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[41]
LGX818	DMNQXV8	Moderate	Increased metabolism of Triazolam caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[42]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Triazolam and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[43]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Triazolam and Lasmiditan.	Migraine [8A80]	[44]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Triazolam caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[45]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Triazolam and Flibanserin.	Mood disorder [6A60-6E23]	[46]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Triazolam and Thalidomide.	Multiple myeloma [2A83]	[47]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Triazolam caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[10]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Triazolam caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[48]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Triazolam caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[49]
Teduglutide	DMYOAKS	Moderate	Altered absorption of Triazolam caused by Teduglutide.	Neonatal malabsorption syndrome [KB89]	[50]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Triazolam caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[51]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Triazolam and Levomethadyl Acetate.	Opioid use disorder [6C43]	[21]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Triazolam and Apraclonidine.	Optic nerve disorder [9C40]	[52]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Triazolam caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[13]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Triazolam caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[53]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Triazolam and Oxymorphone.	Pain [MG30-MG3Z]	[11]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Triazolam and Dezocine.	Pain [MG30-MG3Z]	[11]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Triazolam and Buprenorphine.	Pain [MG30-MG3Z]	[54]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Triazolam and Hydrocodone.	Pain [MG30-MG3Z]	[11]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Triazolam caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[55]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Triazolam caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[19]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Triazolam caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[56]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Triazolam due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[10]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Triazolam and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[57]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Triazolam due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[10]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Triazolam due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[10]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Triazolam due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[10]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Triazolam due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[10]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Triazolam due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[10]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Triazolam caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[58]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Triazolam caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[10]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Triazolam caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[13]
Armodafinil	DMGB035	Moderate	Increased metabolism of Triazolam caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[59]
LEE011	DMMX75K	Moderate	Decreased metabolism of Triazolam caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[60]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Triazolam caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[61]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Triazolam caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[10]
Amiodarone	DMUTEX3	Minor	Potentiate the pharmacologic effects by the combination of Triazolam and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[62]
-----------


⏷ Show the Full List of 91 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Docusate sodium	E00563	23673837	Surfactant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------


⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Triazolam 0.25 mg tablet	0.25 mg	Oral Tablet	Oral
Triazolam 0.125 mg tablet	0.125 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7313).
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
7	Drug Interactions Flockhart Table
8	Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
9	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
10	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
11	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
12	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
13	Cerner Multum, Inc. "Australian Product Information.".
14	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
15	Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
16	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
17	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
18	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
19	Ahonen J, Olkkola KT, Neuvonen PJ "Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers." Br J Clin Pharmacol 40 (1995): 270-2. [PMID: 8527290]
20	Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
21	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
22	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
23	Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
24	Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS "Coadministration of nefazodone and benzodiazepines: 2. a pharmacokinetic interaction study with triazolam." J Clin Psychopharmacol 15 (1995): 320-6. [PMID: 8830062]
25	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
26	Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
27	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
28	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
29	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
30	Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6. [PMID: 6140941]
31	Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796]
32	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
33	Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
34	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
35	Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
36	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
37	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
38	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
40	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
41	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
42	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
43	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
44	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
45	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
46	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
47	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
48	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
49	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
50	Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
51	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
52	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
53	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
54	Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
55	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
56	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
57	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
58	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
59	Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
60	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
61	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
62	Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]